Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have been assigned an average rating of "Buy" from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $21.00.

ARTV has been the topic of several recent analyst reports. HC Wainwright began coverage on shares of Artiva Biotherapeutics in a research note on Monday. They issued a "buy" rating and a $20.00 target price on the stock. Needham & Company LLC reissued a "buy" rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday, November 13th.

Artiva Biotherapeutics Stock Down 0.6 %

ARTV traded down $0.06 during midday trading on Monday, reaching $10.58. 36,709 shares of the company's stock were exchanged, compared to its average volume of 117,709. The company's 50-day moving average is $11.41. Artiva Biotherapeutics has a one year low of $9.68 and a one year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Equities research analysts expect that Artiva Biotherapeutics will post -4.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARTV. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at about $42,000. Franklin Resources Inc. bought a new stake in shares of Artiva Biotherapeutics during the third quarter valued at approximately $7,435,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at approximately $623,000. Wellington Management Group LLP bought a new position in Artiva Biotherapeutics in the 3rd quarter worth approximately $2,912,000. Finally, Samsara BioCapital LLC acquired a new position in Artiva Biotherapeutics during the 3rd quarter worth $4,506,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.